AMBITION4NCT07931599
A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Change in glycated haemoglobin (HbA1c)
Timeframe: From baseline (week 0) to week 52
Secondary (3)
Relative change in body weight
Change in triglycerides
Change in waist circumference
Arms and interventions
ZenagamtideExperimental
Participants will receive zenagamtide subcutaneously.
SemaglutideActive comparator
Participants will receive semaglutide subcutaneously.
Placebo zenagamtidePlacebo comparator
Participants will receive placebo matched to zenagamtide subcutaneously.
Placebo semaglutidePlacebo comparator
Participants will receive placebo matched to semaglutide subcutaneously.
Drugs: Zenagamtide, Semaglutide, Placebo zenagamtide, Placebo semaglutide
Sites
152 sites in 16 countries
United States 41, China 18, Japan 9, Saudi Arabia 8, South Korea 8, United Kingdom 8, Bulgaria 7, Croatia 7, Serbia 7, Brazil 6, Portugal 6, Spain 6, Taiwan 6, Argentina 5, Hungary 5, Poland 5